Invited Speaker Biographical Summaries  by unknown
 Volume 2 • Number 1 • 1999
VALUE IN HEALTH
 
© ISPOR 1098-3015/99/$10.50/51 51–58
 
51
 
JEAN-PHILIPPE ASSAL MD
 
University Hospital, Geneva, Switzerland
 
Following initial training in intermediary metabo-
lism, Dr. Assal studied clinical diabetology and en-
docrinology as a research fellow in Boston for almost
4 years. In 1975 he opened the Diabetes Treatment
& Teaching Unit in the Department of Medicine,
University Hospital, Geneva, giving great attention
to the prevention of long-term complications, such
as amputations. Dr. Assal was appointed Professor
of Medicine by the University of Geneva Medical
School, responsible for the educational approach in
therapy of patients with chronic diseases. In 1995 his
unit became the Division of Therapeutic Education
for Chronic Diseases. Dr. Assal is involved in increas-
ing awareness of patient education and of the global
integrated approach to diabetes care, holding yearly
summer university workshops. He works on the im-
plementation of an educational approach by HCPs in
the field of therapeutic patient education. He was one
of the cofounders of the Diabetes Education Study
Group of the EASD. Dr. Assal works in close collabo-
ration with the World Health Organization (WHO).
Since 1983 his division has been a WHO Collaborat-
ing Center for reference and research in diabetes edu-
cation, giving him a broad knowledge base in various
healthcare systems and approaches to chronic pa-
tients in many different countries. From 1–4 June
1994, Dr. Assal held an international congress in
Geneva, entitled “Patient Education 2000,” spon-
sored by the Geneva Medical School and WHO,
bringing together leading world specialists in varying
chronic diseases. In 1997 Dr. Assal was asked by
WHO-Euro to produce an expert report in the fields
of Therapeutic Patient Education (TPE) and long-
term follow-up of chronic diseases. This report de-
tails training programs for HCPs in the field of TPE.
From November 1998, Dr. Assal has been responsi-
ble for a new curriculum in his medical school: thera-
peutic patient education.
 
WERNER BROUWER MSc
 
Erasmus University, Rotterdam, The Netherlands
 
Werner Brouwer MSc is an economist. He studied at
the Erasmus University, Rotterdam in The Nether-
lands. Since 1996, he has worked for the institute for
Medical Technology Assessment, which is a part of
the Erasmus University, Rotterdam. His main re-
search area is the methodology of cost-effectiveness
analysis, particularly the incorporation and measure-
ment of productivity costs (or indirect nonmedical
costs).
 
JONATHAN COOKE MPharm, PhD
 
South Manchester University Hospitals NHS Trust, 
Manchester, UK
 
Jonathan Cooke received his Bachelor’s degree in
pharmacy from the School of Pharmacy at the Uni-
versity of Bradford. While working in Bradford hos-
pitals, he earned his Master’s in Clinical Pharmacy.
In Leeds he ran the drug information center at St.
James’s Hospital and established the clinical phar-
macy training program, later to become a focus for
the Master’s course in Clinical Pharmacy. As Direc-
tor of Clinical Pharmacy, he led pharmaceutical care
teams and undertook collaborative research pro-
grams in medication compliance, outreach therapeu-
tic detailing and optimizing outcomes research into
antimicrobial utilization (which led to the award of a
Doctorate from the School of Studies in Pharmacol-
ogy at the University of Bradford). During this time
he was also awarded an American Society of Health-
System Pharmacists Research Foundation Award,
the first such recognition for work undertaken out-
side North America. He moved to his present posi-
tion of Director of Pharmacy for South Manchester
University Hospitals NHS Trust in 1990. In this po-
sition, he is secretary to two Drug and Therapeutics
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Committees, a member of the Research and Ethics
Committee, and Divisional Representative for the
executive R&D group. He leads the management
group for Drug Information for the North West
Health Region of England and is course director for
the Pharmacoeconomics module for the MSc/
Diploma in Pharmacy Practice at the University of
Manchester. He is on the board of the National
Health Services (NHS) Centre for Reviews and Dis-
semination Economic Evaluation Database at the
University of York, which is available at its Web site.
Dr. Cooke has over 60 publications and has written
chapters for a number of standard texts. He is on a
number of journal editorial boards and is an advisor
on medicine usage to the World Health Organiza-
tion (WHO). He was a founder board member of
the International Society for the Economic Evalua-
tion of Medicines (ISEEM). He was a founder board
member of the UK Drug Utilization Research Group,
and belongs to the European Association of Hospital
Pharmacists, The European Society of Clinical Phar-
macy, The International Pharmaceutical Federation
(FIP), and The American Society of Health System
Pharmacists. His current research interests include
pharmacoeconomics, outcomes research, drug utili-
zation, and formulary/medicines management.
 
PETER GARNET DAVEY MD, FRCP
 
MEMO, University of Dundee, Dundee, Scotland
 
Peter Garnet Davey is Reader in Clinical Pharmacol-
ogy and Infectious Diseases and Head of Pharmaco-
economics, Medicines Monitoring Unit (MEMO),
University of Dundee, Ninewells Hospital & Medi-
cal School, Dundee, Scotland; and Honorary Reader
in Management, University of St. Andrews. Other
positions currently held by Dr. Davey are: President,
Health Economics Group in Scotland (1995 to
present); Chairman, European Pharmacoeconomics
Advisory Board, Bayer AG (1995 to present); and
editorial board member of 
 
Pharmacoeconomics
 
 and
 
Clinical Performance & Quality Healthcare.
 
 In the
area of pharmacoeconomics research, Dr. Davey
completed postgraduate training in health economics
at the Health Economics Research Unit at the Uni-
versity of Aberdeen in 1984 and has over 10 years
experience of pharmacoeconomics applied to anti-
infectives. In 1996, Dr. Davey joined MEMO as
Head of Pharmacoeconomics, directing research
covering all major therapeutic areas. Dr. Davey has
evolved from an infectious disease physician with an
interest in economic evaluation to a pharmacoecon-
omist with an interest in antibiotics. In addition to
Dr. Davey’s research interests in pharmacoeconom-
ics, he maintains an active research program on the
clinical pharmacology of antimicrobials, including
kinetics, adverse event monitoring, clinical trials,
and evaluation and writing of treatment guidelines.
Dr. Davey has published over 50 publications in
peer-reviewed journals and written invited chapters
on both pharmacoeconomics and antimicrobial che-
motherapy. The subjects of his most recently pub-
lished economic evaluation publications include near
patient testing of INR for anticoagulant monitoring,
ambulatory monitoring of blood pressure, eradica-
tion therapy for H. pylori infection, and home/out-
patient IV antibiotic services. Invited chapters in sev-
eral major textbooks include 
 
The Oxford Textbook
of Medicine, Avery’s Drug Treatment, 4th Edition,
 
and
 
 Antibiotic and Chemotherapy, 7th Edition
 
.
 
MICHAEL DRUMMOND 
BSc, MCom, DPhil
 
University of York, York, UK
 
Michael Drummond is Professor of Economics and
Director of the Centre for Health Economics at the
University of York. His particular field of interest is
the economic evaluation of healthcare treatments
and programs. He has undertaken evaluations in a
wide range of medical fields, including care of the
elderly, neonatal intensive care, immunization pro-
grams, services for people with AIDS, eye health-
care, and pharmaceuticals. He is the author of two
major textbooks and more than 350 scientific pa-
pers, has acted as a consultant to the World Health
Organization, and was project leader of a European
Union Project on the Methodology of Economic
Appraisal of Health Technology. From January
1988 until December 1991, he was a member of the
Medicines Commission in the United Kingdom. He
is currently President of the International Society of
Technology Assessment in Health Care.
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JEAN PAUL GAGNON MSc, PhD
 
Hoechst Marion Roussel, Inc., Kansas City, Missouri, US
 
Jean Paul Gagnon is Director of Health Economics
Policy at Hoechst Marion Roussel, Inc., in Kansas
City. He received a BSc in Pharmacy and an MSc in
Pharmacy Administration from the University of
Connecticut, and a PhD in Pharmacy Administration
from Ohio State University. He is a former professor
and division head of Pharmacy Administration in the
School of Pharmacy at the University of North Caro-
lina, presently serving as adjunct professor in the
schools of pharmacy at the University of Kansas and
the University of Missouri at Kansas City. He has
practiced pharmacy in various practice settings, and
has completed a number of research studies on pre-
scription pricing, consumer attitudes toward phar-
maceutical services, pharmacy patronage motives,
drug use, the effects of public policy decisions on
drug distribution systems and pharmacy services,
and the cost-effectiveness of drugs. He has presented
numerous talks to pharmacy groups and has been
the author or co-author of approximately 70 articles
in professional journals. In 1981–82, he was a Rob-
ert Wood Johnson Health Policy Fellow in Washing-
ton, DC, working as a committee staff person on En-
ergy and Commerce’s Subcommittee on Health. In
1983, he was made an Academy Fellow of the Amer-
ican Pharmaceutical Association Academy of Phar-
maceutical Sciences. He was president of the Ameri-
can Association of Colleges of Pharmacy for the
1985–86 year. Dr. Gagnon received the 1986 Ameri-
can Pharmaceutical Association Foundation/Academy
of Pharmaceutical Sciences Research Achievement
Award in Economic, Social, and Administrative Sci-
ences. He is Past-President of the Association of Phar-
macoeconomics and Outcomes Research (APOR),
now the International Society for Pharmacoeconom-
ics and Outcomes Research (ISPOR). He is currently
Treasurer of the American Pharmaceutical Associa-
tion, serves on the American Foundation for Phar-
maceutical Education’s Board of Grants, is a trustee-
at-large for the United States Pharmacopoeia. In his
present position, he is responsible for the involve-
ment of Hoechst Marion Roussel, Inc. on many
fronts of health economics.
 
LIVIO GARATTINI PhD
 
CESAV, Milan, Italy
 
Livio Garattini graduated in Business Administra-
tion with a thesis in Economics from L. Bocconi Uni-
versity, Milan, in 1983. He has been the director of
CESAV—the Centre for Health Economics Angelo
and Angela Valenti of the Mario Negri Institute—
from its inception in January 1992. He is at present a
member of the international publishing board of the
 
Journal of Outcomes Management
 
 (published by
Turner White Communications) and a member of
the editorial board of 
 
Eurohealth
 
 (published by the
European Health Policy Research Network and LSE
Health). CESAV is currently running some economic
evaluations alongside clinical trials and prospective
costs of illnesses.
 
GREGORY P. GILMET MD, MPH
 
Blue Care Network of Michigan, Southfield, Michigan, US
 
Gregory P. Gilmet MD, MPH, a board-certified spe-
cialist in Allergy and Immunology and Pediatrics, is
Vice President and Medical Director of Quality
Management and Health Outcomes Research at
Blue Care Network of Michigan (BCNM). Located
in Southfield, Michigan, BCNM is a 600,000 mem-
ber mixed-model managed care organization and is
the largest HMO in Michigan. Dr. Gilmet received
his medical degree from the University of Michigan
School of Medicine in Ann Arbor, Michigan. He
completed a residency in pediatrics at Michael Reese
Medical Center in Chicago, Illinois, a fellowship in
clinical pharmacology at the Ohio State University
College of Pharmacy in Columbus, Ohio, and a fel-
lowship in allergy and immunology at the Univer-
sity of Michigan, Department of Internal Medicine.
Dr. Gilmet also received a Master of Public Health
degree at the University of Michigan School of Pub-
lic Health. He is a Certified Managed Care Execu-
tive of the American Association of Health Plans.
Currently, Dr. Gilmet directs BCNM’s quality man-
agement, physician credentialing, and medical data
management departments. He supervises wellness
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and disease management initiatives, HEDIS report-
ing, statistical analyses, and physician performance
reporting at both the regional and statewide levels. A
contributor to the medical and administrative litera-
ture, Dr. Gilmet has been a featured speaker at na-
tional and international conferences on a diversity of
topics of scientific, clinical, and administrative inter-
est. Dr. Gilmet is a Fellow of the American Academy
of Allergy, Asthma, and Immunology; the American
Academy of Pediatrics; and a member of the Ameri-
can College of Physician Executives. He is Chair of
the Immunization Task Force and a member of the
Quality of Care Committee of the American Associ-
ation of Health Plans, as well as a Liaison Member
of the Advisory Committee on Immunization Prac-
tices of the Centers for Disease Control and Preven-
tion. Dr. Gilmet serves on a number of advisory
boards, including the Immunization Action Coali-
tion, and the National Advisory Board of the Robert
Wood Foundation.
 
JOEL W. HAY PhD
 
University of Southern California School of Pharmacy, 
Los Angeles, California, US
 
Joel W. Hay is the QSAD Centurion Associate Pro-
fessor at the USC School of Pharmacy. He is Found-
ing Chair of the Department of Pharmaceutical Eco-
nomics and Policy, with a joint appointment in the
Department of Economics at the University of
Southern California. His previous positions include:
Senior Research Fellow, the Hoover Institution,
Stanford University (1985–1992); Senior Policy Ana-
lyst, Project HOPE (1983–1985); and Assistant Pro-
fessor, Department of Behavioral Sciences and
Community Health, and Department of Econom-
ics, University of Connecticut (1980–1984). Dr.
Hay has authored or co-authored over 60 peer-
reviewed scientific articles. Dr. Hay has served as a
consultant to the US Health Care Financing Admin-
istration, the US Agency for Health Care and Policy
Research, the US Centers for Disease Control and
Prevention, the US Public Health Service, the US
Food and Drug Administration, the US Environ-
mental Protection Agency, the Government of
Hungary, the Hong Kong Medical Executives Asso-
ciation, the World Bank, the California AIDS Com-
mission, the California Medi-Cal Drug Advisory
Board, the County of San Diego Medically Indigent
Adult program, and the County of Sacramento
Homeless Program. He has also consulted on eco-
nomic issues with several pharmaceutical compa-
nies. Dr. Hay has written numerous health-related
op-eds published in papers such as the 
 
Wall Street
Journal
 
, the 
 
San Francisco Chronicle
 
, the 
 
San Diego
Union
 
, the 
 
Sacramento Bee
 
, and 
 
Newsday
 
. Dr. Hay
serves as a Member of the Expert Advisory Panel on
Drug Utilization Review, United States Pharma-
copoeial Convention; the Research and Graduate Af-
fairs Committee, American Association of Colleges
of Pharmacy; and the JAMA Web Site HIV/AIDS
Editorial Review Panel. Dr. Hay was a Founder and
an elected member of the Board of Directors of the
International Society for Pharmacoeconomics and
Outcomes Research. He is Editor-in-Chief of 
 
Value
in Health
 
, the Journal of the International Society
for Pharmacoeconomics and Outcomes Research.
 
ALAN L. HILLMAN MD, MBA, FACP
 
University of Pennsylvania School of Medicine, 
Philadelphia, Pennsylvania, US
 
Dr. Hillman is Associate Professor of Medicine and
Health Care Management at the University of Penn-
sylvania’s School of Medicine and the Wharton
School of Business. He directs the Center for Health
Policy at Penn’s Leonard Davis Institute for Health
Economics, a leading academic health services and
policy research think tank. Also at Penn, he is a Se-
nior Scholar in Clinical Epidemiology and a member
of the Comprehensive Cancer Center research pro-
gram. In the past Dr. Hillman has been Associate Di-
rector of the University of Pennsylvania Medical
Group Practice, where he planned, implemented,
and ran innovative managed care clinical practices in
a traditional academic center. As a noted authority
on managed care and the economics of new medi-
cines and technologies, Dr. Hillman has received re-
search support from many federal agencies, public
and private foundations, and industry. He advises
international corporations, state and federal legisla-
tors, government agencies, and academic centers,
and was a member of the President’s task force on
healthcare reform. Dr. Hillman lectures internation-
ally. Dr. Hillman has won many awards and honors,
including the 1990 Article of the Year Award from
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the Association for Health Services Research (AHSR),
as well as the AHSR’s Young Investigator Award
given for significant contributions to health services
research and health economics early in one’s career.
In 1995, he was elected to membership in the Ameri-
can Society of Clinical Investigation (ASCI), the In-
ternational Who’s Who of Professionals, and the
Directory of Major Economists 1700–1995. Dr.
Hillman is a fellow of the American College of Phy-
sicians and a member of numerous professional and
scientific societies and boards. Dr. Hillman has
intimate knowledge of the managed care industry
through his analyses of the contractual arrangements
between physicians and HMOs. His benchmark arti-
cles were the first to investigate the financial incen-
tives used to influence the practice patterns of physi-
cians. He was described by the 
 
New England Journal
of Medicine
 
 as “the most prolific researcher” in the
area of physician behavior under managed care. Dr.
Hillman has also analyzed mandatory Medicaid
managed care programs, studied exemplary HMO
quality assurance systems, and examined methods of
safeguarding quality in managed competition. His
ongoing research efforts in technology assessment in-
clude economic evaluations of new technologies, fo-
cusing on developing methodology to avoid bias and
to convert data from controlled, clinical trials into
information relevant to the way doctors actually
practice. Dr. Hillman established and ran an inter-
disciplinary task force, which developed the first
voluntary principles to guide behavior between
health economics researchers and their source of fi-
nancial support. Dr. Hillman’s teaching and clinical
responsibilities include patient care and supervision
of house officers and medical students. He teaches
healthcare policy at the Wharton School and has
been recognized for excellence in teaching by the
University. Currently, he is leading Penn’s effort to
develop a new clinical and research information sys-
tem with an infrastructure to facilitate real-time,
community-based research. Dr. Hillman graduated
with honors from Cornell University where he pur-
sued an interdisciplinary major in Science, Technol-
ogy and Society. He attended Cornell University
Medical College, where he was a member of the
AOA honor society and received awards as the out-
standing member of his graduating class. Following
a residency in internal medicine at the New York
Hospital-Cornell Medical Center in New York, Dr.
Hillman became a fellow in the Robert Wood
Johnson Foundation Clinical Scholars Program, dur-
ing which time he received an MBA with distinction
from the Wharton School and was elected to the
Beta Gamma Sigma honor society.
 
THOMAS KURSCHEID MD, MPH
 
Institute for Health Economics at the University of 
Cologne, Cologne, Germany
 
Thomas Kurscheid was born in Bensberg, Germany.
His premedical studies at the “Semmelweis” Univer-
sity of Budapest, Hungary, were completed in 1986
and his medical studies at the University of Budapest
and University of Cologne, Germany in 1992. He
completed his public health studies at the Heinrich-
Heine University, Düsseldorf, Germany. He received
an Advanced life support certificate, Sportsmedicine
certificate, and Specialist GP certificate from the Ger-
man Medical Council in 1996. After working several
years as a physician, he specialized in general medi-
cine and sports medicine. At the same time, he car-
ried out postgraduate work in public health at the
University of Düsseldorf, focusing on health econom-
ics. In early 1997 he began working with the Institute
for Health Economics and Clinical Epidemiology,
University of Cologne, as well as with the Depart-
ment of Health Economics at the Knoll AG (BASF
Pharma) in Ludwigshafen. He is currently focusing on
the health economic impacts of public health relevant
diseases such as obesity and coronary heart disease.
 
KARL W. LAUTERBACH MD, ScD
 
Institute for Health Economics at the University of 
Cologne, Cologne, Germany
 
Professor Lauterbach was trained as a physician
in Germany and the United States. He received
his MD from the Heinrich-Heine University in Düs-
seldorf. He studied public health with a focus on
health policy and management and epidemiology at
the Harvard School of Public Health, where he re-
ceived an MPH degree and an ScD degree. Cur-
rently, he is Director of the Institute for Health Eco-
nomics and Clinical Epidemiology at the University
of Cologne. His work focuses on cost-effectiveness
studies, clinical trials, medical guideline develop-
ment and implementation, and medical ethics.
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CLAUDE LE PEN PhD
 
Paris-Dauphine University, Paris, France
 
Claude Le Pen is Professor of Economics at Paris-
Dauphine University and former dean of the Depart-
ment of Applied Economics. He studied economics
and business administration in HEC business school
in Paris. He then moved to a doctoral program in
Paris Panthéon-Sorbonne University; his main disser-
tation topic was “The Economics of Public Employ-
ment.” In 1984 he turned to health economics, spe-
cializing in the economic assessment of medical
technologies and in the organization and manage-
ment of the healthcare sector. He has been ap-
pointed a member of several state commissions
within the Ministry of Heath, namely the Transpar-
ency Commission in charge of delivering reimburse-
ment authorization for new pharmaceutical prod-
ucts; the Health Account Commission, the working
group for the elaboration of guidelines for economic
evaluation of pharmaceuticals; and the committee
for development and accreditation of physicians net-
working. He was rapporteur of the working group
on the Completion of the Single Market for Pharma-
ceuticals at the European Union level. He is the main
editor of 
 
Filières & Réseaux
 
, a monthly publication
for healthcare professionals. Recently, he created
CLP-Santé, a consulting company for healthcare eco-
nomics. CLP-Santé writes public health and health
economics reports: topics of the latest reports in-
clude the development of pharmaceutical companies
in opthalmology, the economics of maintenance ther-
apy for intravenous drug users, the impact of tax in-
centives on pharmaceutical R&D expenditures, the
impact of new AIDS therapy on hospital costs. He
has written several books, the latest (in press) on the
recent changes in medical practice and in health in-
surance systems. He has written or co-authored about
100 scientific papers.
 
ANDREW DAVID MORRIS MB, ChB, 
MSc, MD, MRCP
 
University of Dundee, Dundee, Scotland
 
Andrew Morris is Senior Lecturer in Medicine and
Honorary Consultant Physician at the University of
Dundee, Department of Clinical Pharmacology,
Ninewells Hospital and Medical School. He received
his MB and ChB in 1987; his MRCP (UK) in 1990;
his MSc in 1992; and his MD 1994 from the Univer-
sity of Glasgow. Dr. Morris has published four
books and chapters, 36 peer-review journal papers,
44 abstracts, and seven journal articles. His most re-
cent publications are: “Adherence to insulin therapy,
glycemic control and ketoacidosis in insulin-depen-
dent diabetes,” 
 
The Lancet
 
, 1997;350:1505–1510;
“The Diabetes Audit and Research in Tayside Scot-
land (DARTS) Study: electronic record linkage to
create a diabetes register,” 
 
British Medical Journal
 
1997; 315:524–528; “Angiotensin converting en-
zyme inhibitors are associated with hospitalization
for severe hypoglycemia in patients with diabetes,”
 
Diabetes Care
 
 1997;20:1363–1367; “Diabetes asso-
ciated lower limb amputation in the community: a
fifteen-year follow-up study,” 
 
Diabetes Care
 
 1998;
21:738–743; “Salt depletion impairs insulin sensitiv-
ity in type 2 diabetes,” 
 
Journal of Clinical Endocri-
nology and Metabolism
 
 1998;83:1552–1557; and
“Which drugs benefit diabetic patients after myocar-
dial infarction?” 
 
Diabetic Medicine
 
 1998;15:282–
289. Dr. Morris is investigator or senior investigator
for numerous grants.
 
FRANK J. E. PEYS
 
IBES/BIGE, the Belgian Institute of Health Economics, 
Brussels, Belgium
 
Frank J. E. Peys (born in Antwerp, Belgium on Feb-
ruary 20, 1950) received his pharmacy degree at the
University of Leuven, Belgium in July 1973. He also
received official recognition as an industrial pharma-
cist and was made responsible for medical promo-
tion. In 1995 he followed the course of Health Eco-
nomics at the University of Antwerp. He started his
professional career as Product Manager for several
franchises at Janssen Pharma, The Netherlands,
from 1974 until 1980. Between 1980 and 1990 he
was Marketing and General Manager for Janssen
Belgium, Luxembourg. In 1991 he became Director
Public Affairs for the European Janssen Group of
companies. In January 1994 he was appointed Di-
rector of IBES/BIGE, the Belgian Institute of Health
Economics, located in Brussels. The IBES/BIGE is an
 Biographical Summaries
 
57
 
independent nonprofit association, founded in 1991.
In the beginning the active members were the most
prominent pharmaceutical companies in Belgium
and the professional association AGIM/AVGI (the
Belgian association for the pharmaceutical industry).
Since 1996 the IBES/BIGE has been financed by the
whole professional association. IBES/BIGE wants to
contribute to a better way of thinking about health
and pharmacoeconomics issues in Belgium. Other
than in-house research, it mainly cooperates with
university centers, scientific associations and with
governmental and private research centers active in
the same field. To that purpose, IBES/BIGE is a
member of several national and international associ-
ations and societies dealing with healthcare policy
and health and pharmacoeconomics. An important
relationship was built up with the PEC (Pharmaco-
economic Committee) of the BESPE (Belgian Society
of Pharmacoepidemiology) within the international
ISPE society. It was this PEC committee that pub-
lished, in November 1995, the proposal for method-
ological guidelines for economic evaluation of phar-
maceuticals in Belgium.
 
JOAN ROVIRA PhD
 
Soikos, University of Barcelona, Barcelona, Spain
 
Joan Rovira received a PhD in Economics from the
University of Barcelona in 1982. His professional
field is teaching and research in economic theory and
health economics. He has been a reader in the Faculty
of Economic Science in the University of Barcelona
since 1975 and Research Director of Soikos since
1988. He is coordinator and lecturer of postgraduate
Health Economics at the University of Barcelona, and
teaches courses in Applied Economics, Healthcare
and Hospital Management organized by institutions
working in the sector. Dr. Rovira is also a consultant
to the European Office of the World Health Organi-
zation, and a specialist in economic evaluation in
health and social care, cost-benefit analysis, evalua-
tion of expensive technology, and economic analysis
of health insurance organizations, and health cooper-
ativism. His published work is in the area of health
and social service economics, in particular, economic
evaluation.
 
DAVID A. WOOD MB, ChB, MSc, 
FRCP, FESC
 
University of London, Imperial College of Science 
Technology and Medicine, London, UK
 
Professor David A. Wood is Foundation Chair of
Clinical Epidemiology, Cardiac Medicine, National
Heart and Lung Institute, Imperial College School of
Medicine, Imperial College of Science Technology
and Medicine, University of London. Professor Wood
is also Honorary Consultant Cardiologist to the
Royal Brompton and Harefield Hospitals NHS Trust
and Hammersmith Hospitals NHS Trust. He re-
ceived his MB, ChB from the University of Dundee in
1974; his MRCP (UK) from the Royal College of
Physicians of Edinburgh 1979; his MSc in Epidemiol-
ogy with Distinction, University of London in 1981.
He was awarded the FRCP from the Royal College of
Physicians of London and of Edinburgh in 1991, and
FESC from the European Society of Cardiology. His
specialty is cardiovascular medicine. His current pro-
fessional appointments are: Chairman, Second Joint
European Society of Cardiology; European Athero-
sclerosis Society and European Society of Hyperten-
sion Task Force on Prevention of Coronary Heart
Disease in Clinical Practice (1997–); British Cardiac
Society representative on the National Heart Forum
(1990–1994 and 1997–); Convenor, Joint British
Cardiac Society, British Hyperlipidemia Association
and British Hypertension Society Working Party on
Prevention of Coronary Heart Disease in Clinical
Practice (1996–); Member of European Society of
Cardiology Scientific and Clinical Initiatives Com-
mittee (1996–1998); Member of the Scientific Com-
mittee of the XIII World Congress of Cardiology
(1996-); Member of the Strategy Group on coronary
heart disease prevention of the Commission of the
European Communities (1996–); External Scientific
Consultant to the American College of Cardiology
on a US survey (ACCEPT) of secondary prevention
practice (1996–); Past Chairman, Scientific Commit-
tee of the Working Group on Epidemiology and Pre-
vention, European Society of Cardiology (1996–
1998); Member Epidemiology and Prevention Com-
mittee, British Cardiac Society (1995–); Chairman,
European Society of Cardiology, European Athero-
sclerosis Society and European Society of Hyperten-
sion Joint Implementation Group on Coronary Pre-
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vention (1994–). Professor Wood is a member of
many medical and scientific societies and has numer-
ous scientific publications with over 25 publications
in the past 5 years.
 
HERBERT F. K. ZÖLLNER MD
 
World Health Organization, Copenhagen, Denmark
 
Dr. Zöllner, a German national, was educated in
Nuremberg, Germany, completing his graduate stud-
ies with a PhD in Economics at the University of
Colorado, US. Dr. Zöllner’s technical fields of spe-
cial interest include health policy, health econom-
ics, healthcare reform, and health services manage-
ment. Following a period as a research economist
in the US, in 1971 Dr. Zöllner joined the World
Health Organization in Geneva as economist for re-
search in epidemiology and communication sciences;
he was the first macro economist ever to be ap-
pointed by the organization. In 1976, Dr. Zöllner
transferred to WHO’s Regional Office for Europe
in Copenhagen as Regional Officer for Health Eco-
nomics, where he systematically built up a program
on health economics. In 1989 he took up a position
in executive management, in Strategic Planning and
Coordination, with responsibilities for program
budget, strategic projects, and key aspects of exter-
nal cooperation and subsequently acting as depart-
ment head for a few years. He is currently Regional
Advisor for Health Economics and Policy Analysis.
Since 1990, Dr. Zöllner has been the focal point for
the development of the Health for All policy in Eu-
rope, a policy which has recently been renewed and
reaffirmed by the 51 Member States during the
WHO Regional Committee held in Copenhagen
this year. Dr. Zöllner is widely known in the field
of economics of healthcare, areas where he contin-
ues to make an active contribution to development
and technical cooperation.
